Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration.
Mojica
G
G
Hariprasad
S M
SM
Jager
R D
RD
Mieler
W F
WF
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D012189:Retrospective Studies
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab